HEAD NECK CANCER

This early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given throug…

This phase II trial tests whether adding the targeted drug nimotuzumab to immunotherapy and chemotherapy before surgery can improve outcomes for people with locally advanced head and neck cancer. About 182 participants will receive the combination or standard treatment. The main …

This phase 3 trial tests a new treatment for people with high-risk head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. Participants receive radiation therapy combined with two drugs (nimotuzumab and benmelstobart) to see if this approach improves dis…

This study tests a new drug called OM-RCA-01, an antibody that blocks a protein called FGFR1 found on some cancer cells. About 58 adults with metastatic kidney, lung, prostate, breast, or head and neck cancers that express FGFR1 will receive the drug by IV every two weeks. The go…

This pilot study is testing whether a combination of two targeted drugs (nimotuzumab and toripalimab) plus standard chemotherapy can shrink locally advanced tonsillar cancer before surgery. Ten adults with resectable tumors will receive the treatment for 2-4 cycles, then have sur…

This early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The ma…

This study tests whether adding the targeted drug nimotuzumab to standard radiation therapy helps control advanced head and neck cancer better than radiation alone. It is for 335 adults whose cancer has spread locally but who cannot take platinum-based chemotherapy. The main goal…

This early-phase trial is testing a new drug called RiMO-301, given as an injection directly into the tumor, along with radiation therapy and an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination is safe and can shrink tumors in people with advanced hea…

This early study is testing a new imaging agent called FL-261 in 12 people with advanced cancers like lung, colorectal, or head & neck cancer. The agent targets a protein called c-MET that is often found on cancer cells. Researchers want to see if FL-261 scans can safely and accu…

This study tests if a special ultrasound using a contrast agent (Sonazoid) can find sentinel lymph nodes as accurately as the standard radioactive tracer method in people with melanoma, breast cancer, or head & neck cancer. About 91 adults will take part, and the goal is to see i…

This study tests whether a special PET-CT scan (micro-PET-CT) can accurately show where head and neck cancer ends, compared to standard lab tests. Ten adults with operable head and neck tumors will have their surgical specimens scanned and then checked under a microscope. If succ…

This study tests whether a specially trained nurse-led team can help people recover better after head and neck cancer surgery. The team includes nurses, doctors, dietitians, and counselors who create a personalized care plan. Researchers will compare 80 patients who get this extr…

This early-stage study tests a non-invasive procedure that uses focused ultrasound to create a tiny lesion in the brain's pain center. It is for 20 adults with head, neck, or brachial cancer whose pain is not controlled by opioids. The goal is to see if it is safe and can reduce …

Some head and neck cancer patients experience a tumor return in an area already treated with radiation. Surgery may not be an option, and standard radiation risks harming healthy tissue. This study tests proton therapy, which delivers radiation more precisely to the tumor while s…

This study looks at genetic and immune changes in laryngeal dysplasia, a precancerous condition of the voice box. Researchers will compare tissue samples from 3 patients to see if certain immune cells (TILs) differ between low-risk and high-risk lesions. The goal is to find marke…

This study is testing whether a special PET scan taken 6 weeks after starting pembrolizumab (an immunotherapy drug) can predict how well the drug works at 3, 6, and 9 months in people with advanced head and neck cancer. Researchers will enroll 25 patients whose cancer has returne…

This study looks at whether giving written, guideline-based information to head and neck cancer patients and their dentists can improve their knowledge and decisions about dental care. About 132 participants will fill out surveys before and after reading the materials. The goal i…